Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 1;31(3):323-328.
doi: 10.53854/liim-3103-6. eCollection 2023.

Candida auris: the new fungal threat

Affiliations
Review

Candida auris: the new fungal threat

Francesco Pallotta et al. Infez Med. .

Abstract

Candida auris is an emergent fungal pathogen of particular concern. Since its first identification in Japan in 2009, it rapidly spread all over the world, including Italy. The main concern related to the diffusion of this fungus is its antifungal resistance. It is speculated that about 90% of isolates are resistant to fluconazole, 30% to amphotericin B and 5% to echinocandins; furthermore, some cases of pan-antifungal resistance have been described. Critically ill patients are particularly at risk of being colonized by this yeast and person-to-person transmission may generate hospital outbreaks. In fact, C. auris can survive on inanimate surfaces for a long time and commonly used disinfectants are not effective. Additionally, devices such as central venous catheters (CVCs) or urinary catheters are particularly at risk of being colonized, representing a possible source for the development of bloodstream infections caused by C. auris, which carries a high mortality rate. Given its capability to spread in the hospital setting and the limited therapeutic options it is of outmost importance to promptly identify C. auris. However, commonly used biochemical tests frequently misidentify C. auris as other Candida species; currently the best identification techniques are MALDI-TOF and molecular methods, such as PCR of the ITS and D1/D2 regions of the 28s ribosomal DNA. Whole genome sequencing remains the gold standard for the phylogenetic investigation of outbreaks. The majority of cases of colonization by C. albicans will not cause bloodstream infections and contact precautions and surveillance of contacts will be sufficient. When invasive fungal infections occur, echinocandins still represent the first therapeutic choice. A combination therapy or the use of novel antifungals (such as ibrexafungerp or fosmanogepix) would be required for echinocandin resistant strains. In conclusion, C. auris represents a growing threat because of its antifungal resistance characteristics, its difficult identification and its easy spread from person to person. The aim of this mini-review is to summarize the main aspects concerning this pathogen.

Keywords: Candida auris; antifungal resistance; epidemiology; novel therapies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41–44. Erratum in: Microbiol Immunol2018; 62(3)205. - PubMed
    1. Du H, Bing J, Hu T, et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 16(10):e1008921. 202. - PMC - PubMed
    1. Sanyaolu A, Okorie C, Marinkovic A, et al. Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection. Infect Chemother. 2022;54(2):236–246. - PMC - PubMed
    1. Briano F, Magnasco L, Sepulcri C, et al. Candida auris Candidemia in critically ill, colonized patients: cumulative incidence and risk factors. Infect Dis Ther. 2022;11(3):1149–1160. - PMC - PubMed
    1. Geremia N, Brugnaro P, Solinas M, Scarparo C, Panese S. Candida auris as an emergent public health problem: a current update on european outbreaks and cases. Healthcare (Basel) 2023;11(3):425. - PMC - PubMed

LinkOut - more resources